American Century Companies Inc. Makes New $232,000 Investment in Eyepoint Pharmaceuticals, Inc. $EYPT

Key Points

• American Century Companies Inc. made a new investment of approximately $232,000 in Eyepoint Pharmaceuticals, acquiring 42,860 shares during the 1st quarter.
• Eyepoint Pharmaceuticals reported a net loss of ($0.85) earnings per share for the most recent quarter, missing analyst expectations.
• Analysts have set a consensus target price of $26.86 for Eyepoint Pharmaceuticals, with a consensus rating of "Buy".

American Century Companies Inc. bought a new stake in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 42,860 shares of the company's stock, valued at approximately $232,000. American Century Companies Inc. owned about 0.06% of Eyepoint Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in EYPT. Nuveen LLC bought a new stake in shares of Eyepoint Pharmaceuticals during the 1st quarter valued at $1,056,000. Invesco Ltd. lifted its stake in Eyepoint Pharmaceuticals by 174.3% in the 1st quarter. Invesco Ltd. now owns 42,948 shares of the company's stock worth $233,000 after purchasing an additional 27,291 shares in the last quarter. Swiss National Bank lifted its stake in Eyepoint Pharmaceuticals by 12.4% in the 1st quarter. Swiss National Bank now owns 112,400 shares of the company's stock worth $609,000 after purchasing an additional 12,400 shares in the last quarter. Deutsche Bank AG lifted its stake in Eyepoint Pharmaceuticals by 67.5% in the 1st quarter. Deutsche Bank AG now owns 357,442 shares of the company's stock worth $1,937,000 after purchasing an additional 144,060 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Eyepoint Pharmaceuticals by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 3,834,368 shares of the company's stock worth $20,782,000 after purchasing an additional 31,141 shares in the last quarter. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

Eyepoint Pharmaceuticals Stock Performance

NASDAQ EYPT opened at $14.01 on Friday. The firm's 50 day moving average price is $10.71 and its 200-day moving average price is $8.06. Eyepoint Pharmaceuticals, Inc. has a 52-week low of $3.91 and a 52-week high of $14.37. The company has a market cap of $965.71 million, a PE ratio of -5.23 and a beta of 1.93.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.18). Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. The business had revenue of $5.33 million for the quarter, compared to the consensus estimate of $6.82 million. On average, analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on EYPT shares. Mizuho decreased their target price on shares of Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating on the stock in a research report on Friday, May 16th. HC Wainwright upped their price target on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Royal Bank Of Canada initiated coverage on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, June 17th. They issued an "outperform" rating and a $28.00 target price on the stock. Finally, Chardan Capital restated a "buy" rating and issued a $27.00 target price on shares of Eyepoint Pharmaceuticals in a research note on Thursday, August 7th. Seven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Eyepoint Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $26.86.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

Want to see what other hedge funds are holding EYPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.